Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • SMT bags 2 years...

    SMT bags 2 years contract with Italian Public Hospitals for 10,000 DES stents

    Written by supriya kashyap kashyap Published On 2017-11-04T09:21:47+05:30  |  Updated On 4 Nov 2017 9:21 AM IST
    SMT bags 2 years contract with Italian Public Hospitals for 10,000 DES stents

    Mumbai: Sahajanand Medical Technologies (SMT), through its Italian partner EUKON S.r.l., has signed an agreement with Emilia Romagna region in Italy to deliver approximately 10,000 Supraflex in the next 2 years.


    This agreement was signed after Supraflex DES won against 9 other DES after 8 months of technical and economical evaluations during the regional tender process concluded few weeks ago. The tender process evaluated the products on basis of quality as well as price offerings from Boston Scientific, Biotronik, Biosensor, Cardinal Health, Envision, Eucatech, Meriland Terumo.


    “We had one shot and we hit the bull’s eye!” said GennaroBroya de Lucia, Sole Director of EUKON;


    “The partnership with SMT gave us all the ammunition to step into a difficult market segment where an extremely fine balance in required between the needs of the interventional cardiologists, who only ask for top quality devices, and the national healthcare system, whose focus is to decrease the health care costs” he added.


    SMT’s Head of Western Europe Gaurav Goel commented: “It's the first time in Europe that an Indian driven team has proven its mettle against the established DES companies. We are in sync with the necessities of the current generation of operators and are agile and innovative. Just like our product Supraflex, we are more ‘flexible’ and we are fully ready to build on this important milestone to boost to our expansion in Italy and rest of Europe.


    Emilia Romagna is one of the most populous regions of north Italy, with 15 cath labs performing the 10% of the Italian PTCA, listing cities like Bologna, Ferrara, Modena, Parma, Piacenza, Rimini, Forlì, Ravenna and Reggio Emilia.


    Supraflex™, the 3rdgen DES from SMT, has the lowest strut (60µm) thickness among all the available sirolimus-eluting coronary stents, without compromising radial strength. It comes with the broadest sizes range currently available for PTCA, a safety proven bioabsorbable polymer and an optimized drug release.


    These features, the continuous clinical outcomes, and a great post-sales support are making Supraflex™, the choice of a growing family of hemodynamists.

    Coronary StentsEmilia RomagnaGaurav GoelGennaroBroya de LuciaItalian Public HospitalSahajanand Medical TechnologiesSMT
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok